|
Fast Facts About Genzyme Corporation
CEO:
|
Henri A. Termeer
President 1983, CEO 1985, Chairman 1988
|
Founded:
|
1981
|
2007 Revenues:
|
$3.8 billion
|
2007 R & D Spending:
|
$640 million
|
Employees Worldwide:
|
More than 10,000
|
Headquarters:
|
Cambridge, MA
|
Exchange and Symbol:
|
Nasdaq, GENZ
|
Areas of Focus:
|
Genetic Diseases, Renal Disease, Orthopaedics, Transplant/Immune Diseases, Oncology/Endocrinology, Genetics/Diagnostics
|
|
|
|
Top Products, based on FY 2007 Revenue:
|
Product Name
|
Disease/Condition
|
Revenue 2007
|
Cerezyme® (imiglucerase for injection)
|
Gaucher disease
|
$1.13 billion
|
Renagel® (sevelamer hydrochloride)
|
end-stage renal disease
|
$603 million
|
Fabrazyme® (agalsidase beta)
|
Fabry disease
|
$424 million
|
Synvisc® (hylan G-F 20)
|
osteoarthritis of the knee
|
$242 million
|
|
|
Key Pipeline Products:
|
Product Name
|
Disease/Condition
|
MozobilTM (plerixafor)
|
stem cell transplant
|
alemtuzumab (Campath®)
|
multiple sclerosis
|
Clolar® (clofarabine)
|
adult acute myeloid leukemia
|
mipomersen
|
high-risk hypercholesterolemia
|
International Presence:
|
Genzyme has more than 80 locations in over 40 countries, including 17 manufacturing facilities and 9 genetic testing laboratories; the company's products are available in nearly 90 countries.
|
Charitable Contributions, FY 2007:
|
Global product donations, $110 million; U.S. cash contributions, $14 million.
|
|
Home
